US 7,537,771 B2
	Expression system
Ethel Diane Williamson, Wiltshire (United Kingdom); Julie Miller, Wiltshire (United Kingdom); Nicola Jane Walker, Wiltshire (United Kingdom); Leslie William James Baillie, Wiltshire (United Kingdom); Paula Thomson Holden, Wiltshire (United Kingdom); Helen Claire Flick-Smith, Wiltshire (United Kingdom); Helen Lisa Bullifent, Wiltshire (United Kingdom); Richard William Titball, Wiltshire (United Kingdom); and Andrew William Topping, North Yorkshire (United Kingdom)
Assigned to The Secretary of State for Defence, Salisbury, Wiltshire (United Kingdom)
Appl. No. 10/332,282 PCT Filed Jul. 06, 2001, PCT No. PCT/GB01/03065 § 371(c)(1), (2), (4) Date Apr. 11, 2003, PCT Pub. No. WO02/04646, PCT Pub. Date Jan. 17, 2002.
Claims priority of application No. 0016702.3 (GB), filed on Jul. 08, 2000.
Prior Publication US 2003/0170263 A1, Sep. 11, 2003
Int. Cl. A61K 39/07 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 38/00 (2006.01)

U.S. Cl. 424—246.1  [424/184.1; 424/185.1; 424/236.1; 530/300; 530/324]

9 Claims

1. An immunogenic reagent comprising one or more isolated polypeptides, wherein the one or more isolated polypeptides alone or together are no more than three full domains of full length Protective Antigen (PA) of Bacillus anthracis; wherein the one or more isolated polypeptides comprise at least one of domain 1, region 1b of domain 1, or domain 4 of the PA; and wherein the immunogenic reagent produces an immune response that is protective against B. anthracis.